OUP (Osage University Partners)

AssetWatch specializes in proactive and predictive maintenance solutions aimed at preventing unplanned downtime for global manufacturers. The company offers an extensive remote condition monitoring service that integrates wireless sensors and communication hubs with sophisticated software. These wireless vibration and temperature sensors gather critical machine health data, which is analyzed using machine learning algorithms and the expertise of condition monitoring engineers. This analysis provides actionable insights that go beyond simple pass/fail assessments, enabling manufacturers to transition from a reactive to a proactive maintenance culture. By delivering prescriptive recommendations, AssetWatch supports manufacturers in optimizing their maintenance processes and enhancing operational reliability.

Virtue AI specializes in AI security and compliance, offering a decentralized, open platform designed for the public good. Their platform provides comprehensive risk assessments for AI applications, ensuring regulatory compliance and offering AI Safety leaderboards for performance benchmarking.

Virtue AI specializes in AI security and compliance, offering a decentralized, open platform designed for the public good. Their platform provides comprehensive risk assessments for AI applications, ensuring regulatory compliance and offering AI Safety leaderboards for performance benchmarking.

Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Overland AI specializes in the development of autonomous navigation technology tailored for off-road vehicles. The company focuses on creating artificial intelligence-based solutions that enhance off-road autonomy, particularly for mission-critical sectors such as defense and national security. By utilizing machine learning and robotic systems, Overland AI provides modular software designed to facilitate the autonomous navigation of unimproved roads and rugged terrain. This technology enables clients to operate vehicles independently in challenging environments like mines, construction sites, and disaster zones, addressing the need for reliable transportation solutions in demanding conditions.

VeraDermics is a dermatology company focused on developing innovative solutions for skin conditions, particularly warts. The company has created a dissolvable microneedle patch that delivers immunotherapy painlessly, stimulating the body's immune response to combat the wart virus. This patch is designed to be applied like a bandage and remains on the skin for less than an hour. During this time, the microneedles, made from immune stimulators embedded in a polymer matrix, dissolve and are implanted into the skin. After the adhesive backing is removed, the microneedles continue to dissolve over the following weeks, releasing immune stimulators directly into the wart. This method not only provides a pain-free treatment option but also simplifies the administration process for medical practitioners and enhances patient comfort.

Xscape Photonics specializes in the development of photonic chips aimed at enhancing bandwidth connections within high-performance computing systems and data centers. By leveraging photonics technology, the company focuses on creating scalable, high-bandwidth solutions that are both energy-efficient and cost-effective. These chips facilitate improved connectivity among computing elements, significantly reducing power consumption while increasing the speed and efficiency of communications. Xscape Photonics' innovations support the advancement of applications in artificial intelligence, machine learning, and simulation hardware, positioning the company as a key player in the evolution of next-generation computing infrastructure.

Quantum Circuits, Inc. specializes in the development and manufacture of quantum computers utilizing superconducting devices. Founded in 2015 and located in New Haven, Connecticut, the company aims to innovate in the field of quantum computing by delivering full-stack systems that efficiently scale. Led by Dr. Robert Schoelkopf, a prominent figure in quantum science, Quantum Circuits employs a unique dual-rail quantum qubit design that incorporates built-in hardware error detection and conversion. This approach allows for a highly scalable error-corrected system, requiring significantly fewer physical qubits per logical qubit and providing a more efficient pathway to fault-tolerant quantum computing. By focusing on solid-state quantum bits, the company enables clients to perform error-free computations, thereby accelerating research and advancing the practical applications of quantum technology.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Quintessent Inc., founded in 2019 and based in Santa Barbara, California, specializes in the commercialization of quantum dot-based lasers and photonic integrated circuits. The company focuses on developing optical connectivity technology that enhances large-scale computing systems. By utilizing advanced semiconductor materials and innovative laser architectures, Quintessent's solutions facilitate the scaling of high-bandwidth communication channels within optical networks. This technology supports applications in optical networking, deep learning systems, and sensing, positioning Quintessent at the forefront of advancements in these critical areas.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

AssetWatch specializes in proactive and predictive maintenance solutions aimed at preventing unplanned downtime for global manufacturers. The company offers an extensive remote condition monitoring service that integrates wireless sensors and communication hubs with sophisticated software. These wireless vibration and temperature sensors gather critical machine health data, which is analyzed using machine learning algorithms and the expertise of condition monitoring engineers. This analysis provides actionable insights that go beyond simple pass/fail assessments, enabling manufacturers to transition from a reactive to a proactive maintenance culture. By delivering prescriptive recommendations, AssetWatch supports manufacturers in optimizing their maintenance processes and enhancing operational reliability.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

Verve Motion specializes in the development of exo-suits aimed at assisting workers engaged in physically demanding tasks. The company utilizes a combination of robotics, apparel design, and movement science to create lightweight wearables crafted from textile materials. These exo-suits are designed to adapt to the movements of the wearer, providing necessary support and force during critical moments while remaining nonrestrictive at other times. By focusing on safety and comfort, Verve Motion enhances the capabilities of workers in various industries, promoting a more efficient and secure working environment.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Kate Therapeutics is a biotechnology company dedicated to developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases. The company employs advanced technology platforms to enhance tissue-specific delivery and gene regulation, overcoming significant challenges associated with current gene therapies. By utilizing innovative capsids, Kate Therapeutics achieves superior muscle transduction and effectively de-targets the liver, allowing for more efficient tissue transduction at lower viral doses. This approach addresses key limitations in muscle gene delivery, aiming to improve treatment outcomes for patients with muscle and heart conditions.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Hack The Box Ltd. is an online platform founded in 2017, based in Folkestone, United Kingdom, that focuses on enhancing skills in penetration testing and cybersecurity for individuals, organizations, and educational institutions. The platform offers a variety of guided and exploratory learning experiences, allowing users to improve both offensive and defensive security skills. Through challenges that simulate real-world scenarios and capture-the-flag style tasks, Hack The Box enables users to learn new techniques and refine their hacking abilities, thereby preparing them for various cybersecurity challenges. This makes it a valuable resource for professionals seeking to advance their expertise in the rapidly evolving field of cybersecurity.

Opsys Technology Co., Ltd. specializes in designing and developing optical communication products, focusing on solutions that utilize advanced fiber optics technologies. The company's product offerings include LIDAR systems, RF over fiber links for various applications such as remote antenna and distributed antenna systems, as well as mixed signal solutions for aircraft and maritime environments. Opsys Tech is also active in sectors requiring temperature and strain sensors, as well as data center switching technologies. With a strong emphasis on autonomous vehicle control and intelligent sensors, the company is committed to innovating new applications within the optical market. Founded as a spinoff from a leading optical communication firm, Opsys Tech is based in Holon, Israel, and continues to expand its portfolio to meet the demands of modern technological advancements.

Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

Normunity is a biotechnology company focused on developing precision immuno-oncology medicines, specifically a new class known as immune normalizers. These medicines aim to target novel mechanisms that enhance the body’s natural immune response against cancer. In collaboration with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is researching newly-discovered mechanisms of immune disruption in cancer, utilizing proprietary discovery platforms to explore the intricate interactions between cancer and the immune system. The company is advancing a pipeline of immune normalizers, which includes initial drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune function in cancer. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Metalenz, Inc. is a company focused on the research, development, and production of advanced optical components, particularly for consumer electronics such as mobile phones and computers. Established in 2016 and headquartered in Weston, Massachusetts, with an additional office in San Francisco, Metalenz specializes in meta-optics that utilize structured Huygens' surfaces to manipulate light properties. This innovative approach allows for the creation of ultra-thin planar optics that enable high-resolution full-color imaging. By offering smaller and lighter alternatives to traditional lenses, Metalenz supports businesses in miniaturizing their products, enhancing their design flexibility and functionality in various high-volume applications, including automotive and other electronic devices.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

AssetWatch specializes in proactive and predictive maintenance solutions aimed at preventing unplanned downtime for global manufacturers. The company offers an extensive remote condition monitoring service that integrates wireless sensors and communication hubs with sophisticated software. These wireless vibration and temperature sensors gather critical machine health data, which is analyzed using machine learning algorithms and the expertise of condition monitoring engineers. This analysis provides actionable insights that go beyond simple pass/fail assessments, enabling manufacturers to transition from a reactive to a proactive maintenance culture. By delivering prescriptive recommendations, AssetWatch supports manufacturers in optimizing their maintenance processes and enhancing operational reliability.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Brimstone is a company that has developed a carbon-negative process for producing ordinary Portland cement and supplementary cementitious material. Founded in 2019 and based in Oakland, California, Brimstone's innovative technology employs carbon-free calcium silicate rock instead of traditional limestone, resulting in a product that matches the performance of conventional materials while remaining cost-competitive at scale. This advancement aims to provide the construction industry with a cleaner and more sustainable alternative to traditional cement production methods.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients suffering from neurodegenerative diseases. The company leverages a technology platform that incorporates human genetics and patient-derived neuronal cells to identify and validate new disease pathways linked to lysosomal dysfunction and the inappropriate activation of the innate immune system. Vanqua Bio focuses on creating small-molecule activators of glucocerebrosidase and advancing programs that target the innate immune system, with the aim of addressing the progression of various neurological disorders. Through its efforts, the company seeks to provide healthcare professionals with transformative treatment options for patients facing these challenging conditions.

Corelight, Inc. provides network visibility solutions tailored for information security professionals, focusing on network traffic analysis to combat cyber threats. The company offers a suite of products, including Corelight sensors and a fleet manager, built upon the open-source Bro framework, which delivers actionable, real-time data to enhance cybersecurity efforts. Founded in 2013 and headquartered in San Francisco, California, Corelight serves enterprises, government agencies, and higher education institutions, enabling them to gain deep insights into network traffic and effectively detect and respond to cyberattacks. The company also maintains additional offices in Santa Clara, California, and Columbus, Ohio.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Verve Motion specializes in the development of exo-suits aimed at assisting workers engaged in physically demanding tasks. The company utilizes a combination of robotics, apparel design, and movement science to create lightweight wearables crafted from textile materials. These exo-suits are designed to adapt to the movements of the wearer, providing necessary support and force during critical moments while remaining nonrestrictive at other times. By focusing on safety and comfort, Verve Motion enhances the capabilities of workers in various industries, promoting a more efficient and secure working environment.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Hack The Box Ltd. is an online platform founded in 2017, based in Folkestone, United Kingdom, that focuses on enhancing skills in penetration testing and cybersecurity for individuals, organizations, and educational institutions. The platform offers a variety of guided and exploratory learning experiences, allowing users to improve both offensive and defensive security skills. Through challenges that simulate real-world scenarios and capture-the-flag style tasks, Hack The Box enables users to learn new techniques and refine their hacking abilities, thereby preparing them for various cybersecurity challenges. This makes it a valuable resource for professionals seeking to advance their expertise in the rapidly evolving field of cybersecurity.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, dedicated to developing innovative antibody-drug conjugate therapies targeting CD46. The company focuses on treating late-stage multiple myeloma and prostate cancer, among other indications. Its platform is designed to advance therapies for both adenocarcinoma and neuroendocrine cancers, providing healthcare professionals with effective treatment options for patients facing these advanced stages of cancer.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Coho Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2019 by Bruce Clurman and Jayson Punwani. The company specializes in developing molecular glue therapeutics aimed at protein degradation, which is a novel approach to treating conditions such as cancer, neurodegeneration, and other serious diseases. By leveraging this innovative technology, Coho Therapeutics seeks to create medicines that can effectively prevent and combat various life-threatening illnesses, contributing to advancements in healthcare.

Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

Menlo Security, Inc. is a cybersecurity company based in Mountain View, California, that specializes in providing a cloud-based isolation platform designed to protect organizations from cyberattacks. Founded in 2012, the company offers solutions that eliminate the threat of malware from websites, documents, and emails by executing all web content in the cloud. This approach allows users to safely interact with online content without the risk of exposure to malicious threats. Menlo Security serves a diverse clientele, including Fortune 500 companies and financial institutions, through a network of resellers in North America and internationally. The company has expanded its operations across regions including EMEA, Australia, New Zealand, Japan, APAC, and DACH.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Palladio Biosciences, Inc. is a biotechnology company focused on developing transformative medicines for orphan diseases of the kidney. Founded in 2015 and based in Horsham, Pennsylvania, the company is in the clinical stage and specializes in therapeutics aimed at renal diseases, particularly polycystic kidney disease (PKD). One of its key developments is Lixivaptan, a selective vasopressin V2 receptor antagonist designed to treat PKD, a life-threatening genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Palladio Biosciences aims to provide innovative treatment options that can help prevent the progression of kidney diseases.

Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company utilizes a functional genomics discovery platform based on human cell lines to identify novel therapeutic targets, addressing the underlying biology of neurodegenerative diseases. By leveraging advancements in neuroscience and human genetics, Nido aims to create precise medications that restore healthy cell function and improve treatment options for conditions that significantly impact patient quality of life.

SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focusing on RISC-V architecture. Established in 2015 and headquartered in San Mateo, California, with additional offices in locations such as Oregon, Texas, India, Taiwan, and France, SiFive provides a range of products including multi-core application processors, embedded microcontrollers, and system-on-chip solutions tailored for various applications such as IoT and wearables. The company emphasizes the use of open-source technology to enable faster and more cost-effective hardware development. By offering software development kits, toolchains, and customized silicon products, SiFive aims to democratize access to advanced semiconductor solutions, accelerating innovation for businesses of all sizes.

Aerovate Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing innovative treatments for patients with rare cardiopulmonary diseases. The company's primary focus is on AV-101, a proprietary inhaled dry powder formulation of the drug imatinib, designed specifically for the treatment of pulmonary arterial hypertension (PAH). This formulation enables targeted delivery of the medication directly to affected lung tissues, thereby minimizing systemic side effects commonly associated with traditional treatments. Established in 2018, Aerovate aims to provide meaningful improvements in the lives of those suffering from these serious conditions.

Censys, Inc. specializes in internet scanning and asset identification solutions, offering a platform that enables organizations to gain a real-time view of global networks and devices. Founded in 2017 and based in Ann Arbor, Michigan, Censys provides tools for attack surface management, allowing users to discover unknown assets, monitor remote workforces, and identify threat actors. Its internet intelligence platform is designed for threat hunting and exposure management, creating a comprehensive dataset that enhances visibility into vulnerabilities and internet-exposed infrastructure. This enables businesses to efficiently locate and manage the devices, networks, and infrastructure that are critical to their operations.

Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed specifically for the treatment of acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, allowing for selective targeting of the cancer without harming normal cells. This innovative approach seeks to minimize the toxicities associated with traditional immunotherapies, which often affect both cancerous and healthy tissues. By protecting healthy stem cells from depletion while generating functional immune cells, Vor Biopharma aims to enhance therapeutic outcomes for patients with hematological malignancies.

StreetLight Data, Inc. specializes in cloud-based analytics solutions aimed at enhancing transportation management for both companies and government entities. Its primary product, StreetLight InSight, is an online platform that analyzes mobility patterns through Big Data, transforming anonymous location data from mobile devices into actionable insights for transportation engineers, urban planners, and property developers. Additionally, the company offers RouteScience, which organizes disparate location data into cohesive travel patterns. Founded in 2010 and headquartered in San Francisco, California, with additional locations in Richmond, Virginia, and Vancouver, Canada, StreetLight Data enables users to make informed decisions regarding infrastructure deployment and transportation planning, ultimately contributing to the development of smarter cities.

Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

IonQ, Inc. is a technology company that specializes in the development of general-purpose quantum information computers utilizing a trapped ion approach. Founded in 2015 and based in College Park, Maryland, IonQ focuses on advancing quantum computing capabilities through qubit replication, optical networkability, and optimized algorithms. The company's quantum computers represent a significant shift from classical computing, effectively addressing limitations associated with superposition and entanglement at the atomic level. IonQ provides access to its quantum processors through cloud platforms, offering quantum-computing-as-a-service (QCaaS) to a wide range of customers. Additionally, the company engages in research and development to enhance its quantum technology and supports clients through consulting services aimed at co-developing algorithms for its quantum systems.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing effective and accessible immune cell therapies, primarily targeting cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create a new paradigm for discovering and developing immune cell therapies. ArsenalBio's innovative approach aims to enhance the efficacy and safety of T-cell therapies while reducing costs for providers and broadening patient access. By employing a full-stack research and development engine, ArsenalBio generates multifunctional T-cell medicines through the precise insertion of large synthetic DNA sequences, enabling clinicians to utilize next-generation autologous T-cell therapies to combat cancer more effectively.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, specializing in the development of oral therapeutics for autoimmune diseases. Founded in 2017, the company focuses on innovative treatments for conditions such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Its lead product candidate, NX-13, is a novel, gut-selective agonist targeting the NLRX1 pathway. The company also has a diverse pipeline that includes other internally discovered compounds aimed at novel immunometabolic pathways. By developing first-in-class therapeutics, Landos Biopharma seeks to provide effective treatment options for patients suffering from autoimmune conditions.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Menlo Security, Inc. is a cybersecurity company based in Mountain View, California, that specializes in providing a cloud-based isolation platform designed to protect organizations from cyberattacks. Founded in 2012, the company offers solutions that eliminate the threat of malware from websites, documents, and emails by executing all web content in the cloud. This approach allows users to safely interact with online content without the risk of exposure to malicious threats. Menlo Security serves a diverse clientele, including Fortune 500 companies and financial institutions, through a network of resellers in North America and internationally. The company has expanded its operations across regions including EMEA, Australia, New Zealand, Japan, APAC, and DACH.

Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focusing on RISC-V architecture. Established in 2015 and headquartered in San Mateo, California, with additional offices in locations such as Oregon, Texas, India, Taiwan, and France, SiFive provides a range of products including multi-core application processors, embedded microcontrollers, and system-on-chip solutions tailored for various applications such as IoT and wearables. The company emphasizes the use of open-source technology to enable faster and more cost-effective hardware development. By offering software development kits, toolchains, and customized silicon products, SiFive aims to democratize access to advanced semiconductor solutions, accelerating innovation for businesses of all sizes.

Algorithmia, Inc. provides a platform that facilitates the deployment and management of machine learning models. Founded in 2013 and headquartered in Seattle, Washington, the company enables algorithm developers to create, explore, and share algorithms as web services. Its solution automates MLOps, allowing data scientists and developers to efficiently deploy models into production through a scalable API that can handle various algorithm requests. Algorithmia supports popular frameworks such as TensorFlow, PyTorch, Scikit-learn, and MXNet, and also hosts a public marketplace for algorithms. The company was acquired by DataRobot in 2021, enhancing its capabilities in serving enterprise customers with mission-critical workloads.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.

LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.

Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.

Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed specifically for the treatment of acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, allowing for selective targeting of the cancer without harming normal cells. This innovative approach seeks to minimize the toxicities associated with traditional immunotherapies, which often affect both cancerous and healthy tissues. By protecting healthy stem cells from depletion while generating functional immune cells, Vor Biopharma aims to enhance therapeutic outcomes for patients with hematological malignancies.

KenSci Inc. is a healthcare technology company that has developed a machine learning platform aimed at improving risk management for healthcare providers and payers. Founded in 2015 and headquartered in Seattle, Washington, with additional offices in Hyderabad, India, and Singapore, KenSci's platform enables early intervention by predicting clinical, financial, and operational risks. It integrates healthcare data from various sources, including electronic medical records and claims data, to identify patterns and high-risk markers. The platform features a library of pre-built models and modular solutions that can be incorporated into existing workflows, enhancing hospital operations by reducing costs and improving care coordination. Additionally, KenSci employs Explainable AI models to ensure that its risk predictions are both efficient and accountable. The company also has a strategic partnership with T3k Health, further expanding its impact in the healthcare sector.

Seismos is a data analytics company focused on production optimization through its innovative K-wave technology, which enables real-time monitoring of underground fluid flow during production. Unlike traditional seismic methods, which are time-consuming and costly, Seismos offers a non-invasive, cloud-based solution that provides immediate insights at a significantly lower cost. The company's AI-powered sensing systems utilize advanced acoustic sensing and machine learning to detect and predict anomalies across various sectors, including upstream oil and gas, pipelines, and geothermal markets. By delivering real-time data, Seismos empowers organizations to make informed decisions and enhance operational efficiency without disrupting production processes.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Elementary Robotics, Inc. specializes in manufacturing robots designed to assist humans in various industries, including electronics, automotive, medical, and consumer packaged goods. Founded in 2017 and headquartered in Pasadena, California, with additional offices in Mexico and Chicago, the company focuses on automating quality assurance and traceability processes in AI-assisted manufacturing. Its robots are equipped with advanced software, deep learning AI, and camera systems to capture visual data, enabling real-time decision-making and enhancing the efficiency of production lines. By integrating machine learning and computer vision, Elementary Robotics aims to create intelligent automation solutions that improve productivity and streamline workflows in manufacturing and logistics.

Vector Launch, Inc. is a company that develops software for satellites and launch vehicles to facilitate access to space for micro and nano satellites. Founded in 2016 and headquartered in Tucson, Arizona, it operates additional facilities in Long Beach and San Jose, California. The company aims to connect space startups with affordable and frequent launch options, thereby enhancing access to orbital capabilities at unprecedented speeds and price points. Its focus on low-cost microsatellites not only supports commercial innovations but also addresses complex challenges for national security, providing valuable services to the intelligence community and the Department of Defense. However, Vector Launch faced financial difficulties and filed for reorganization under Chapter 11 in December 2019.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with significant unmet medical needs. The company, based in Oakland, California, was incorporated in 2016 and is a subsidiary of Zogenix, Inc. Modis Therapeutics is advancing its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapeutic candidate is specifically designed to address thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance, increasing mitochondrial DNA copy number, and enhancing cell function, Modis Therapeutics aims to provide meaningful treatment options that can prolong the lives of affected patients.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Infinite Uptime, Inc. offers an integrated industrial solution that combines hardware, cloud analytics, and control software to enhance equipment monitoring and decision-making processes. The company's IoT platform automates predictive maintenance for industrial machines, primarily targeting sectors such as steel, power, cement, chemicals, automotive, and pharmaceuticals. Its industrial data analytics platform (IDAP) identifies patterns in data, assesses overall equipment effectiveness, and detects anomalies in real-time, thereby supporting ISO compliance and monitoring productivity trends. Founded in 2015 and headquartered in Berkeley, California, Infinite Uptime also operates an R&D and technology center in Pune, India, alongside a manufacturing facility in Vadodara, India. The company's innovative approach aims to reduce unplanned downtime, improve overall efficiency, and provide actionable insights into plant performance.

StreetLight Data, Inc. specializes in cloud-based analytics solutions aimed at enhancing transportation management for both companies and government entities. Its primary product, StreetLight InSight, is an online platform that analyzes mobility patterns through Big Data, transforming anonymous location data from mobile devices into actionable insights for transportation engineers, urban planners, and property developers. Additionally, the company offers RouteScience, which organizes disparate location data into cohesive travel patterns. Founded in 2010 and headquartered in San Francisco, California, with additional locations in Richmond, Virginia, and Vancouver, Canada, StreetLight Data enables users to make informed decisions regarding infrastructure deployment and transportation planning, ultimately contributing to the development of smarter cities.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Seismos is a data analytics company focused on production optimization through its innovative K-wave technology, which enables real-time monitoring of underground fluid flow during production. Unlike traditional seismic methods, which are time-consuming and costly, Seismos offers a non-invasive, cloud-based solution that provides immediate insights at a significantly lower cost. The company's AI-powered sensing systems utilize advanced acoustic sensing and machine learning to detect and predict anomalies across various sectors, including upstream oil and gas, pipelines, and geothermal markets. By delivering real-time data, Seismos empowers organizations to make informed decisions and enhance operational efficiency without disrupting production processes.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Embodied, Inc. is a robotics company based in Pasadena, California, specializing in the development of personal companion robots aimed at enhancing care and wellness. Founded in 2016 and formerly known as CareBots, Inc., the company has created Moxie, an interactive robot designed for children that promotes social, emotional, and cognitive development through play-based learning. Drawing on over 14 years of research in socially assistive robotics from the University of Southern California and extensive experience in consumer robotics, Embodied combines advanced artificial intelligence with engaging storytelling and animation techniques. The company's mission is to improve the quality of life for individuals and families by providing life-like, interactive robots that serve as motivators, coaches, and companions, empowering users to improve their own well-being.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Ambiq Micro, Inc. specializes in the development of ultra-low power integrated circuits tailored for power-sensitive applications. The company focuses on creating subthreshold power optimized technology, producing real-time clocks and microcontrollers for various uses, including wearables, smart cards, wireless sensors, and Internet-of-Things (IoT) devices. Founded in 2009 and based in Austin, Texas, Ambiq Micro also maintains offices in San Jose, California, and several locations in China. Its pioneering technology aims to facilitate the creation of next-generation wireless electronics by enabling innovative companies to design products that minimize battery dependency, reduce overall power consumption, and enhance design flexibility. Additionally, Ambiq Micro provides technical support services to its clients, further contributing to its mission of advancing low-power semiconductor solutions.

Medisix Therapeutics, established in 2016 and headquartered in Singapore, is an early-stage biotechnology company specializing in cell therapy. It focuses on developing chimeric antigen receptor (CAR) T-cell therapies to target and treat T-cell lymphomas and leukemias. The company's technology platform is built upon the pioneering work of Professor Dario Campana, MD, PhD, a renowned expert in translational immunology and the founder of CAR-T cell biology. Medisix's proprietary immune engineering approaches enable the targeting of T cell leukemias and lymphomas using cell therapy.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, focused on developing innovative cytokine Synthorin programs for the treatment of cancer and autoimmune disorders. The company's lead product candidate, THOR-707, is a variant of recombinant human IL-2 being explored for various solid tumors, both as a standalone treatment and in combination with immune checkpoint inhibitors. Additionally, Synthorx is working on IL-2 Synthorin for autoimmune conditions, IL-10 Synthorin for immuno-oncology, and IL-15 Synthorins to enhance immune regulation. The company employs advanced synthetic biology techniques, utilizing a novel DNA base pair to create proteins with enhanced specificity, safety, and efficacy. These developments enable the manufacturing of improved therapeutics that can better modulate pharmacological properties compared to traditional biologics. Synthorx, which was established in 2014 and previously known as Alinos, Inc., operates as a subsidiary of Sanofi and holds exclusive rights to its innovative synthetic biology technology derived from research at The Scripps Research Institute.